Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWC202304 is a fixed-dose combination drug developed by Daewoong Pharmaceutical, marketed under the brand name EasyPrep in South Korea. It is indicated for bowel cleansing in preparation for colonoscopy or other endoscopic and radiological procedures. The formulation contains three osmotic laxatives—sodium sulfate, potassium sulfate, and magnesium sulfate—which work by drawing water into the colon to stimulate bowel movements and clear fecal matter. Additionally, it includes simethicone, an anti-foaming agent that reduces gas bubbles in the gastrointestinal tract, thereby improving the clarity of the endoscopic view. In clinical development, DWC202304 has served as the reference control for newer formulations, such as DWJ1609, which adds sodium picosulfate to the mixture.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium sulfate + potassium sulfate + magnesium sulfate + simethicone.